ENGINEERED NRG-1 VARIANTS WITH IMPROVED SELECTIVITY TOWARD ERBB4 BUT NOT AGAINST ERBB3

ENGINEERED NRG-1 VARIANTS WITH IMPROVED SELECTIVITY TOWARD ERBB4 BUT NOT AGAINST ERBB3

The present invention relates to engineered neuregulin-1 variants that selectively activate ErbB4 receptors but do not activate ErbB3 receptors. The invention also provides methods for using such variants to treat heart failure.

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: WANG, Zhulun, BATES, Darren L, LEE, TaeWeon, LIU, Zhi, MICHAELS, Mark L
Format: Patent
Sprache:eng
Schlagworte:
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The present invention relates to engineered neuregulin-1 variants that selectively activate ErbB4 receptors but do not activate ErbB3 receptors. The invention also provides methods for using such variants to treat heart failure.